<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33124">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675439</url>
  </required_header>
  <id_info>
    <org_study_id>ADU-CL-07</org_study_id>
    <nct_id>NCT02675439</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of MIW815 (ADU-S100) in Patients With Advanced/Metastatic Solid Tumors or Lymphomas</brief_title>
  <official_title>A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aduro Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aduro Biotech, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,
      pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral
      injection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number of patients reporting treatment-related adverse events that qualify as dose-limiting toxicities</measure>
    <time_frame>6 months from study start</time_frame>
    <description>Number of patients reporting treatment-related adverse events that qualify as dose-limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose</measure>
    <time_frame>6 months from study start</time_frame>
    <description>Using maximum tolerated dose to identify the recommended dose for future studies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics measured through plasma concentrations</measure>
    <time_frame>6 months from study start</time_frame>
    <description>measured through plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of CD8-TIL counts</measure>
    <time_frame>6 months from study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNA expression analysis of IFN gamma and immunomodulatory genes</measure>
    <time_frame>6 months from study start</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Advanced/Metastatic Solid Tumors or Lymphomas</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADU-S100 administered intratumorally on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxicity, progressive disease and/or treatment is discontinued; starting dose 50 micrograms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADU-S100</intervention_name>
    <arm_group_label>Dose escalation</arm_group_label>
    <other_name>MIW815</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG â‰¤ 1

          -  Willing to undergo tumor biopsies from injected and distal lesions

          -  Must have two biopsy accessible lesions:

               -  * one lesion must be 10 mm and &lt;100 mm in longest diameter, accessible for
                  repeated intratumoral (IT) injection and accessible for baseline and
                  on-treatment biopsies.

                    -  a second (distal) lesion must be accessible for baseline and on-treatment
                       biopsy and must be distinct from the injected lesion.

                    -  tumors encasing major vascular structures (i.e., carotid artery or tumors
                       close to other vital organs), are not considered appropriate

        Exclusion Criteria:

          -  Patients who require local palliative measures such as XRT or surgery

          -  Symptomatic or untreated leptomeningeal disease.

          -  Presence of symptomatic central nervous system (CNS) metastases

          -  Impaired cardiac function or clinically significant cardiac disease

          -  Active autoimmune disease or a documented history of autoimmune disease, except
             vitiligo or resolved childhood asthma/atopy.

          -  Active infection requiring systemic antibiotic therapy.

          -  Known history of Human Immunodeficiency Virus (HIV) infection.

          -  Active Epstein-Barr virus (EBV), HBV (hepatitis B virus) or HCV (hepatitis C virus)

          -  Malignant disease, other than that being treated in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Luke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frank Hodi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center MD Anderson PSC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Funda Meric-Bernstam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sunil Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>February 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
